Business ❯ Pharmaceuticals ❯ Drug Development

Licensing Agreements

International Licensing BioNTech Heart Disease Glenmark Pharmaceuticals Chronic Obstructive Pulmonary Disease (COPD) Cancer Treatments China-Originated Drugs International Partnerships Immune-mediated Diseases Multiple Sclerosis Zaltenibart

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

The rights exchange sets 2026 clinical launches under a split granting Kelun CR-001 in Greater China, leaving SKB105 to Crescent outside China.

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Bristol Myers Squibb and BioNTech partner on $11 billion bispecific antibody cancer drug